Association of reproductive factors with dementia: A systematic review and dose-response meta-analyses of observational studies

Chunying Fu,a,b,1 Wenting Hao,a,b,1 Nipun Shrestha,c Salim S. Virani,d Shiva Raj Mishra,e,f and Dongshan Zhu,a,b,*

aCentre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China
bNHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan, 250012, China
cDepartment of Primary care and mental health, University of Liverpool
dMichael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, United States of America
eAcademy for Data Sciences and Global Health, Kathmandu, Nepal
fSalim Yusuf Emerging Leaders Program, World Heart Federation, Geneva, Switzerland

Summary

Background Associations between endogenous estrogen exposure indicators and risk of subtypes of dementia have been unclear.

Methods Databases (PubMed, EMBASE and Web of Science) were searched electronically on 1st July and updated regularly until 12nd November 2021. Observational studies of English language were selected if reported an effect estimate [e.g., odds ratio (OR), rate ratio (RR) or hazard ratio (HR)] and 95% CI for the association between any exposure (age of menarche, age at menopause, reproductive period, estradiol level) and any endpoint variable [all-cause dementia, Alzheimer’s disease (AD), vascular dementia (VD), cognitive impairment (CI)]. Random-effects models and dose-response meta-analyses were used to calculate estimates and to show the linear/nonlinear relationship. PROSPERO CRD42021274827.

Findings We included 22 studies (475,9764 women) in this analysis. We found no clear relationship between late menarche (≥14 vs <14 years) and dementia, CI in categorical meta-analysis compared to a J-shape relationship in dose-response meta-analyses. Later menopause (≥45 vs <45 years) was consistently associated with a lower risk of all-cause dementia (pooled RR: 0.87, 95%CI: 0.78−0.97, I²=56.0%), AD (0.67, 0.44−0.99, I²=78.3%), VD (0.87, 0.80−0.94) and CI (0.82, 0.71−0.94, I²=19.3%) in categorical meta-analysis, showing similar results in dose-response meta-analyses. An inverse relationship between longer reproductive duration (≥35 vs <35 years) and dementia was observed in dose-response meta-analysis. In addition, estradiol levels after menopause were inversely correlated with the risk of AD and CI.

Interpretation In this study, later menopause and longer reproductive period were associated with a lower risk of dementia, while the relationship for menarchal age was J-shaped. There was an inverse relationship between higher postmenopausal estrogen levels and risk of AD and CI. Longitudinal study are needed to further explore the association between life-time estrogen exposure and risk of subtypes of dementia.

Funding Start-up Foundation for Scientific Research in Shandong University.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Keywords: Menarche; menopause; Reproductive period; Estrogen level; Dementia; Cognitive impairment

Introduction Sex differences have been shown in the epidemiology of dementia.¹ Compared to men of the same age, women aged 60 to 69 years showed 1.9 times higher prevalence (108 cases versus 56 cases per 10,000 persons) of Alzheimer’s disease (AD) than men, while the prevalence of vascular dementia (VD) was 1.8 times higher...
Research in context

Evidence before this study

Previous studies have shown inconsistent findings on the associations between age at menopause, length of reproductive period and risk of dementia.

Added value of this study

Compared with previous studies, we included both pre- and postmenopausal estrogen exposures in the present review, providing a life-course perspective into understanding the relationship between endogenous estrogen exposure and subtypes of dementia. Methodologically, besides using categorized meta-analyses, we also used dose-response meta-analyses to show the linear/non-linear relationship between the exposure and outcome across a continuous exposure spectrum.

Implications of all the available evidence

Later menopause and longer reproductive period were associated with a lower risk of dementia, while the relationship for menarchal age was J-shaped. Higher concentration of endogenous estradiol after menopause was linked to lower risk of AD and CI. Longitudinal, repeat measure designs are needed to examine the association between life-time estrogen exposure and risk of subtypes of dementia using direct measure of serum level of endogenous estrogen before and after menopause.

Methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. This study was registered with PROSPERO, CRD42021274827.

Search strategy and data extraction

Three online databases, PubMed, EMBASE and Web of Science were searched using a combination of search terms as following up to 1st July 2021.

The search strategy included combined terms on: (i) terms related to menarche (“age at menarche”, menarch*, pubert*, “sexual maturation”, precocious, Menarche [Mesh], puberty [Mesh], sexual maturation [Mesh]); (ii) terms related to menopause (“age at menopause”, menopa*, climacteric, perimenopa*, post-menopa*, “onset menopause”, “age at natural menopause”, “final menstrual period”, “final menstruation”, Menopause [Mesh], Climacteric [Mesh], Perimenopause [Mesh], Postmenopause [Mesh]); (iii) terms related to reproductive period (“reproductive timing”, “reproductive time”, “reproductive duration”, “reproductive year”, “reproductive history”, “reproductive span”, “reproductive life span”, “reproductive period”); (iv) terms related to estrogen exposure (“Estrogen”, “Oestrogen”, “estradiol”); (v) terms related to cognitive impairment (Dementia, “Cognitive capability”, “Alzheimer’s disease”, “Cognitive impairment”, “Cognition function”, Alzheimer). The detailed search strategy for each database was listed in eMethods in the Supplement.
First, we imported all searched literature into Endnote and excluded duplicates. The search was limited to studies on human beings and were published in English. Then two investigators screened the titles and abstracts independently and selected the final list of studies in consensus (WTH and CYF). Finally, we extracted the first author’s name, country, study design, exposure variables, outcome variables, covariates adjusted, estimates (e.g., adjusted odds ratio (OR), relative risk (RR) or hazard ratio (HR)) and their 95% CIs. The search was updated on 12nd November 2021.

Study selection
We included studies if they met the following inclusion criteria. (1) Observational studies. (2) Exposure variable at least one of the following: age at menarche, age at menopause, reproductive duration, or concentration of endogenous estrogen after menopause. (3) The endpoint of interest was all-cause dementia, AD, VD, or CI. (4) The study reported an effect estimate (e.g., OR, RR or HR) and the corresponding 95% confidence interval (95% CI) for the association between exposure and endpoint variable.

Exposures of interest
We defined four exposure variables of interest: (1) Age at menarche was the occurrence of a first menstrual period in female adolescence; (2) Age at menopause was defined retrospectively as the cessation of spontaneous menses for 12 months; (3) Reproductive period was the difference between age at menopause and age of menarche; (4) Concentration (pmol/L) of serum estradiol level after menopause was used to indicate post-menopausal estrogen exposure.

Outcomes
The outcomes of interest were the following: all-cause dementia, AD, VD and CI. The presence of dementia, AD and VD was determined by self-reported dementia or AD or VD diagnosed by a doctor, ascertained by medical records. The presence of CI (including MCI) or not was assessed by using scales of Mini-mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA). MMSE<24 or education-specific cut-off points of MMSE (score 17/18 for subjects with no education, 20/21 for subjects with primary school education, and 24/25 for those with secondary school or higher education), and MoCA<26 were used to define CI. MMSE<27 was used to define MCI.

Risk of bias assessment
The Newcastle-Ottawa Scale (NOS) was used to assess risk of bias for systematic review of observational studies. The NOS is an eight-item instrument designed to rate methodological aspects of case-control and cohort studies. A study was given a maximum of one score for items under selection and outcome domain, and two scores under comparability domain. The overall score ranges from 0 to 9 for each study. A score of 0–5, 5–6 and 7–9 was rated as low, moderate and high-quality studies, respectively.

The Agency for Healthcare Research and Quality (AHRQ) scale was used to assess the quality of cross-sectional studies. There were 11 items in total, and each item has three options of yes, no, and not clear. The answer “Yes” will score 1 point, and the answer “No or Not Clear” will score 0 point. The overall score ranges from 0 to 11. A score of 0–3, 4–7 and 8–11 was rated as low, moderate, and high-quality studies respectively.

Statistical analysis
Given the lower than 10% incidence of dementia or MCI (e.g., dementia: 9.87–17.18/1000 person-years, AD: 2.2% (95% CI: 1.6–2.8), MCI: 22.6 (95% CI: 19.6–25.9) and 8.67 (95% CI: 7.0–10.7) per 1000 person-years for less severe and severe cognitive impairment respectively), we approximated HR and OR as RR when pooling the estimates across the studies.

Two types of meta-analysis were performed. We first performed traditional meta-analyses (of categorical exposure variable) to yield a pooled estimate of the association between menstrual age, menopausal age, reproduction duration with each outcome (all-cause dementia, AD, VD, and CI), respectively. Forest plots were used to show results. As categories of exposure variables differed in individual studies and lacked a uniform reference, we recombined the original categories into simplified categories to pool the effect estimates. For example, age at menopause categories: <40, 40–44, 45–49, 50–54, ≥55 years were combined as <45 and ≥45 years. Categorical meta-analysis was not conducted for estradiol level due to large variation between studies. Limited studies precluded further analysis of the association between reproductive factors and VD.

Second, we conducted a dose-response meta-analysis for each exposure-outcome relationship. Step one, we performed a non-linear dose-response meta-analysis for each exposure-outcome relationship, then based on the χ² and p-value calculated in step one, we determined whether a linear (P>0.05) or non-linear (P<0.05) dose-response meta-analysis should be adopted. The Q and I² statistics were used to evaluate the heterogeneity among studies. Higgins et al. (2003) suggested that heterogeneity could be quantified as low, moderate, and high to I² values of 25%, 50%, and 75%, respectively.

Subgroup analysis was performed to investigate sources of heterogeneity by race (white and non-white) and study design (case-control or cohort). Random-effect models were used to pool the RR.
Finally, we performed subgroup analyses based on study design (case-control or cohort) and race (white and non-white). Additionally, to address potential bias and verify our results, we performed various sensitivity analyses by (1) excluding low-quality studies, (2) using a leave-one-out method, (3) Mantel-Haenszel weighting. To investigate the risk of publication bias, we applied the Egger test and visually inspected the funnel plots.

All analyses were carried out using Review Manager, version 5.4 (Nordic Cochrane center), complemented by STATA statistical software, version 15.0 (StataCorp). Generalized least squares for trend estimation (GLST) function was used to conduct dose-response meta-analysis. All statistical tests were based on the two-sided 5% level of significance.

Role of the funding source
The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

Results
Study selection
We identified 7 857 studies from various databases initially. Among them, 7523 were excluded for duplication or for not meeting our inclusion criteria. Thus, 64 studies were left for full paper assessment. Of them, 19 (43.2%) studies lacked information of effect sizes cannot be calculated based on the data provided, 16 (36.3%) were not related to the topic, three (6.8%) had abstract only, three (6.8%) included women using exogenous estrogen therapy, one (2.2%) was a duplicate publication. Finally, 22 articles included (Fig. 1).

Study characteristics
Overall, the 22 studies included 475 9764 women. Studies were published between 1994 and 2020, with women’s age 40 years or older at baseline. Of these studies, seven were done in Asian (3 in China, 1 in Korea, 1 in Japan, 1 in Thailand and 1 in Singapore), six in the USA, eight in Europe (4 in Netherlands, 2 in Sweden, 1

Figure 1. flowchart of included studies.
in Italy, and 1 in French), and one contained women from mixed countries (Cuba, Dominican Republic, Puerto Rico and Venezuela, Peru, Mexico and China). Fourteen were case-control studies, six were cohort studies and two were cross-sectional studies (Table 1 and appendix pp 5–20). Numbers of studies on age of menarche and all-cause dementia, AD, VD, CI were 8, 4, 1, 2 respectively. The numbers for age at menopause were 10, 5, 1, 3 respectively; reproductive period were 6, 3, 1, 3 respectively; postmenopausal endogenous estrogen level were 4, 4, 2, 2 respectively. Numbers of studies for each exposure-outcome by types of estimates reported were shown in appendix p 21.

Most cohort or case-control studies were rated high quality (with scores greater than seven) based on NOS quality assessment tool, and only two studies were rated moderate quality (with a score of six). AHRQ scale for cross-sectional studies also showed that both the two studies were with a high quality (appendix pp 22–23).

Age at menarche and all-cause dementia, AD, VD and CI

Compared to women with earlier age at menarche (≤12 years), categorized meta-analysis showed that menarchal age 13–14 years was borderline associated with lower risk of all-cause dementia (pooled RR=0.93, 95% CI 0.87–1.00, I²=4.8%), while no clear association with AD (Fig. 2). Later menarche (≥17 years) was related to increased risk of VD (1.16, 1.10–1.22) (Supplementary eTable 2) and a borderline significance was found between later menarchal age and increased risk of and CI (pooled RR=1.14, 95% CI 1.00–1.30, I²=0.0%) (Fig. 2). Dose-response meta-analyses showed a J-shape relationship between age at menarche and risk of all-cause dementia and AD. Women with menarche at 13 years had the lowest risk. In addition, a linear relationship was found between menarchal age and risk of CI, and the later of a woman’s menarche, the higher risk of experiencing CI (Fig. 5A and Supplementary eFig. 1).

Age at menopause and all-cause dementia, AD, VD and CI

Compared to women with earlier menopause (<45 years), later menopause (≥45 years) was linked to a decreased risk of all-cause dementia (0.87, 0.78–0.97, I²=56.0%), AD (0.67, 0.44–0.99, I²=78.3%), VD (0.87, 0.80–0.94) and CI (0.82, 0.71–0.94, I²=19.3%) (Fig. 3 and Supplementary eTable 2). Dose-response meta-analyses showed a consistently inverse linear trend, i.e., the later menopausal age, the lower risk of all-cause dementia, AD and CI (Fig. 5B and Supplementary eFig. 1).

Reproductive period and all-cause dementia, AD, VD and CI

Pooled RRs (95% CI) from categorized meta-analyses showed no association between reproductive duration (≥35 years vs <35 years) and risk of all-cause dementia and AD (Fig. 4), while longer reproductive period (>39 years vs <35 years) was related to lower risk of VD (0.81, 0.76–0.86) and CI (0.72, 0.61–0.83, I²=0.0%) (Fig. 4 and Supplementary eTable 2). Dose-response meta-analyses showed an inverse linear relationship between reproductive period and all-cause dementia and CI. A J-shape relationship with AD was also observed, with duration of 37 years had the lowest risk (Fig. 5C and Supplementary eFig. 1).

Estradiol level and all-cause dementia, AD, VD and CI

An inverse linear association was observed between postmenopausal estradiol concentration and risk of AD and CI (one study with CI also included estradiol level in perimenopausal women). As to the link with all-cause dementia, due to the estradiol levels in available studies were all in a lower level (less then 45 pmol/L), we did not find a clear relationship between them (Supplementary eFig. 1). Although no significance was observed with VD, there was a trend that higher postmenopausal concentration of estradiol might be related to increased risk of VD (Supplementary eTable 2).

Subgroup analysis

By design. Overall, the associations of exposures with outcomes in this study were marginally moderated by study design. Taking age at menopause (≥45 vs <45 years) and all-cause dementia for instance, the pooled OR (95% CI) in case-control studies was 0.79 (0.56, 1.12, I²=62%), and the pooled RR (95% CI) in cohort studies was 0.89 (0.84, 0.94) (Supplementary eFig. 2).

By race. In white population, no significant association was observed between reproductive period and all-cause dementia (RR 95%CI: 0.97, 0.65–1.45, I²=0%), while in non-white population, longer reproductive period was linked to lower risk of all-cause dementia (0.87, 0.86–0.88, I²=84.5%) (Supplementary eFig. 3).

Sensitivity analysis

Using the leave-one-out method, we found no studies that influenced the results disproportionately (Supplementary eTable 6). Restriction of the analyses to high-quality studies did not substantially change the pooled estimates (Supplementary eFigure 5). Mantel-Haenszel weighting also yielded similar results (Supplementary eFigure 6).

Publication bias. Limited by the number of studies for exposure-outcome relationship, we only conducted Egger test and visualize funnel plot for studies of age at...
| Study number | Age of menarche | Categories (year) | Effect sizes, 95% CI | Cases | Control | Person | Age range at baseline (year) | Study type | Country |
|--------------|----------------|------------------|---------------------|-------|---------|--------|-----------------------------|------------|---------|
| 5 | (Rasgon, N. L., 2005) | <12 | Age and education | 1.21 (0.85–1.73) | 42 | 192 | 234 | 65–84 | C | Swedish |
| | | 12–14* | | 1 | 592 | 2834 | 3426 | | | |
| | | >14 | | 1.19 (1.03–1.38) | 372 | 1444 | 1816 | | | |
| 18 | (Paganini-Hill, A., 1994) | ≤12* | | 1 | 32 | 175 | 207 | 86.5 (mean) | Cc | USA |
| | | 13 | | 1.14 (0.68–1.73) | 38 | 183 | 221 | | | |
| | | ≥14 | | 1.19 (1.03–1.38) | 60 | 180 | 240 | | | |
| 1 | (Geerlings, M. I., 2001) | ≤12 | Age, education, smoking status, alcohol intake, body mass index, hormone replacement therapy, number of children, and apolipoprotein E genotype. | | 61 | 175 | 207 | ≥55 | ir | Netherlands |
| | | 13 | | 1.83 (1.13–2.96) | 37 | 672 | | | | |
| | | ≥14 | | | | | | | | |
| 11 | (Paganini-Hill, A., 2020) | ≤12* | Education | | 67 | 145 | | ≥90 | ci | USA |
| | | 13 | | 1.18 (0.82–1.70) | 68 | 130 | | | | |
| | | ≥14 | | 1.00 (0.67–1.50) | 74 | 149 | | | | |
| 12 | (Yoo, J. E., 2020) | ≤12 | Age at menarche, age at menopause, parity, duration of breastfeeding, duration of HRT, duration of oral contraceptive use, alcohol consumption, smoking, regular exercise, income, body mass index, hypertension, diabetes mellitus, dyslipidemia and cancer | | 61 | 687 | | | | |
| | | 13–14* | | 1.22 (0.87–1.72) | 68 | 130 | | | | |
| | | 14–15 | | 0.85 (0.61–1.19) | 74 | 149 | | | | |
| | | ≥16 | | | | | | | | |
| 13 | (Prince, M. J., 2018) | per year | Age, education and assets | | 692 | 26461 | | ≥65 | ci | USA |
| | | | | 0.99 (0.94–1.03) | | | | | | |
| 19 | (Najar, J., 2019) | per year | Age at menarche, age at menopause, number of pregnancies, months of breastfeeding, birth year, psychological stress, and hypertension | | NA | 1364 | | 38–60 | ci | Swedish |
| | | | | 0.99 (0.91–1.09) | | | | | | |
| 20 | (Gilsanz, P, 2018) | ≤9 | Age, race/ethnicity, and educational attainment. Midlife factors include body mass index, hypertension, smoking status. Late life factors include stroke, diabetes, and heart failure, mid and late-life factors. | | 14 | 29 | | 40–55 | ci | USA |
| | | 10–13* | | 1.39 (0.82–2.36) | 14 | 29 | | | | |
| | | 14–15 | | 1.00 (0.91–1.11) | 610 | 1484 | | | | |
| | | ≥16 | | 1.27 (1.07–1.50) | 341 | 789 | | | | |
| Number (author, year) | Categories (year) | Covariates adjusted | Effect sizes, 95% CI | Cases | Control | Person | Age range at baseline (year) | Study type | Country |
|-----------------------|-------------------|---------------------|---------------------|-------|---------|--------|-------------------------------|------------|---------|
| 5 # (Rasgon, N. L., 2005) | Age and education | OR 1.64 (1.03–2.61) | NA 1.39 (1.08–1.78) | 27 102 | 75 438 | 1.01 (0.85–1.20) | 1.06 (0.77–1.49) | 1.01 2.602 | 0.96 2.61 |
| 18 # (Paganini-Hill, A., 1994) | NA 0.96 (0.61–1.52) | OR 1.39 (1.08–1.78) | NA 1.05 (0.53–2.09) | 1.27 1.02 | 1.39 1.78 | 1.01 1.20 | 1.05 2.09 | 1.39 1.78 | 1.01 1.20 |
| 1 # (Geerlings, M. I., 2001) | <48* Age, education, smoking status, alcohol intake, body mass index, hormone replacement therapy, number of children, and apolipoprotein E genotype. | OR 1.24 (0.72–2.15) | NA 1.06 (0.53–1.94) | 1.24 1.82 | 1.24 1.82 | 1.06 1.94 | 1.24 1.82 | 1.24 1.82 | 1.06 1.94 |
| 8 # (Coppus, A. M. W., 2010) | <45 Age, education and assets | OR 1.00 (0.99–1.01) | NA 1.00 (0.77–1.31) | 1.00 1.31 | 1.00 1.31 | 1.00 1.31 | 1.00 1.31 | 1.00 1.31 | 1.00 1.31 |
| 11 # (Paganini-Hill, A., 2020) | ≤44* Education | OR 1.19 (0.84–1.68) | NA 1.08 (0.76–1.53) | 1.19 1.68 | 1.19 1.68 | 1.08 1.53 | 1.19 1.68 | 1.19 1.68 | 1.08 1.53 |
| 12 # (Yoo, J. E., 2018) | <40* Age at menarche, age at menopause, parity, duration of breastfeeding, body mass index, hypertension, diabetes mellitus, dyslipidemia and cancer | OR 1.08 (0.96–1.22) | NA 1.06 (0.95–1.19) | 1.08 1.22 | 1.08 1.22 | 1.06 1.19 | 1.08 1.19 | 1.08 1.22 | 1.06 1.19 |
| 13 # (Previc, M. J., 2018) | per year Age, education and assets | OR 1.00 (0.99–1.01) | NA 1.07 (0.94–1.24) | 1.00 1.01 | 1.00 1.01 | 1.07 1.24 | 1.07 1.24 | 1.00 1.01 | 1.07 1.24 |
| 19 # (Najar, J., 2019) | per year Age at menarche, age at menopause, number of pregnancies, months of breastfeeding, birth year, psychological stress, and hypertension | OR 1.07 (1.04–1.10) | NA 1.08 (1.05–1.12) | 1.07 1.10 | 1.07 1.10 | 1.08 1.12 | 1.07 1.10 | 1.07 1.10 | 1.08 1.12 |
| 20 # (Gilsanz, P., 2018) | ≤41 Age, race/ethnicity, and educational attainment. Midlife factors include body mass index, hypertension, smoking status, Late life factors include stroke, diabetes, and heart failure, mid and late-life factors. | OR 1.08 (0.96–1.22) | NA 1.06 (0.95–1.19) | 1.08 1.22 | 1.08 1.22 | 1.06 1.19 | 1.08 1.19 | 1.08 1.22 | 1.06 1.19 |
| 9 # (Ryan, J., 2014) | >50 Baseline cognitive function, recruitment center, age, education level, physical limitations, chronic illness, depression, use of HT at the menopause and current HT use. | OR 1.23 (0.76–2.00) | NA 1.23 (0.72–2.01) | 1.23 2.00 | 1.23 2.00 | 1.23 2.01 | 1.23 2.01 | 1.23 2.00 | 1.23 2.01 |
| Study Type | Country | Reproductive period | Number (author, year) | Categories (year) | Covariates adjusted | Effect sizes, 95% CI |
|------------|---------|---------------------|----------------------|------------------|---------------------|---------------------|
|            |         | Age, education      |          |                  |                     | cases | control | person | age range at baseline (year) |
|            |         |                     |          |                  |                     | 30-39 | 39-49   | 40-49   | <35 | 35-39* | >39 |          |
|            |         |                     |          |                  |                     | 1.15 | 0.82    | 0.82    | 1   | 0.82    | 1.15 | 0.82    |
|            |         |                     |          |                  |                     | 176 | 137     | 157     | 1131 | 2310    | 1136   | 65-84   |

**Covariates adjusted**
- Age and education
- Alcohol intake, body mass index, use of hormone replacement therapy, number of children, and apolipoprotein E genotype.
- Duration of breastfeeding, duration of oral contraceptive use, duration of hormone replacement therapy, use of hormones replacement therapy, number of children, body mass index, hyper tension, diabetes mellitus, dyslipidemia, and cancer.

**Study References**
1. Rasgon, N. L., 2005
2. Geerlings, M. I., 2001
3. Paganini-Hill, A., 2020
4. Yoo, J. E., 2020
5. Prince, M. J., 2018
6. Najar, J., 2019
7. Liu, J., 2019
8.Prince, M. J., 2018
| D) Estradiol level | Number (author, year) | Categories | Covariates adjusted | Effect sizes, 95% CI | Cases | Control | Person | Age range at baseline (year) | Study type | Country |
|-------------------|----------------------|------------|----------------------|----------------------|-------|---------|--------|-----------------------------|------------|---------|
| 2 # (Senanarong, V., 2002) | >5 pg/ml * | NA | | | 1 | 1 | 17 | 68.8(mean) | | Thailand |
| | 1.01–5 pg/ml | | | | 1.13 (0.24–5.46) | 1 | 1 | 17 | | | |
| | ≤1 pg/ml (Non demented) | | | | 6.23 (1.74–22.9) | 6 | 17 | | | | |
| 3 # (Geerlings, M. I., 2003) | ≥0.0 and <7.1 pmol/L* | Age, education, BMI, smoking status, type of menopause, age at natural menopause, and ever use of hormonal replacement therapy | | | | | | | | | |
| | ≥7.1 and <20 pmol/L | | | | 1.58 (0.75–3.35) | 27 | 170 | | | | |
| | ≥20 and ≤67 pmol/L | | | | 1.99 (0.89–4.45) | 27 | 169 | | | | |
| 7 # (Ravaglia, G., 2007) | Low (undetectable)* High (≥10 pg/mL) | Age, age at menopause, education, apolipoprotein E4 genotype, smoking status, and body mass index, stroke, cardiovascular disease, diabetes, hyperhomocysteinemia, serum folate, serum vitamin B12, and serum creatinine | | | | | | | | |
| | | | | | 1.75 (1.05–2.88) | 71 | 433 | 76.2 (mean) | | | |
| 11 # (Paganini-Hill, A., 2020) | (EEEI index) ≤32.6* | Education | | | | | | | | | |
| | 32.7–35.8 | | | | 0.95 (0.68–1.33) | 70 | 142 | | | | |
| | ≥35.9 | | | | 0.77 (0.54–1.08) | 61 | 135 | | | | |
| 23#(Laure Carcaillon.,2014) | Q1: E2 <3.49 pg/mL. | Age and center, education, APOE e4, depressive symptoms, waist-to-hip ratio, Mini-Mental State Examination score at baseline, hypercholesterolemia, and history of myocardial infarction and stroke | | | | | | | | |
| | Q2: 3.49–5.30 pg/mL | | | | 2.20 (1.07–4.52) | 41 | 675 | ≥65 | | | |
| | Q3: 5.30–8.00 pg/mL | | | | 1.46 (0.68–3.15) | 26 | | | | | |
| | Q4: E2 >8.00 pg/mL | | | | 1 | 25 | | | | | |
| | | | | | 2.43 (1.15–5.20) | 40 | | | | | |

Table 1: Characteristics of studies with all-cause dementia by age at menarche, age at menopause, reproductive period and postmenopausal estradiol level.
Notes: * reference group. C, Cc, ir and ci represent cross-sectional study, case-control study, person-year cohort study and cumulative number of cases cohort study, respectively.
NOTE: Weights are from random effects analysis.

**Age at menarche: 13-14 vs ≤ 12 (years)**
- Rasgon, N. L. (2005)
- Paganini-Hill, A. (1994)
- Geerlings, M. I. (2001)
- Paganini-Hill, A. (2020)
- Yoo, J. E. (2020)
- Subtotal (I-squared = 4.8%, p = 0.379)

**Age at menarche: >14 vs ≤ 12 (years)**
- Rasgon, N. L. (2005)
- Paganini-Hill, A. (1994)
- Geerlings, M. I. (2001)
- Paganini-Hill, A. (2020)
- Yoo, J. E. (2020)
- Subtotal (I-squared = 52.2%, p = 0.079)

**Age at menarche and all cause dementia**

**Age at menarche and Alzheimer's disease (AD)**

**Age at menarche and cognitive impairment (CI)**

Figure 2. The associations between age at menarche and risk of (A) all-cause dementia, (B) Alzheimer’s disease, (C) cognitive impairment. The boxes in the forest plot show the effect estimates from the single studies, and the horizontal lines through the boxes illustrate the width of the 95% confidence interval. The size of each box represents the weight (%) of each study in the meta-analysis. The hollow diamonds show the pooled estimates, and the width of diamond represent the 95% confidence interval.
### Figure 3.
The associations between age at menopause and risk of (A) all-cause dementia, (B) Alzheimer's disease, (C) cognitive impairment. The boxes in the forest plot show the effect estimates from the single studies, and the horizontal lines through the boxes illustrate the width of the 95% confidence interval. The size of each box represents the weight (%) of each study in the meta-analysis. The hollow diamonds show the pooled estimates, and the width of diamond represent the 95% confidence interval.
Figure 4. The associations between length of reproductive period and (A) all-cause dementia, (B) Alzheimer’s disease, (C) cognitive impairment. The boxes in the forest plot show the effect estimates from the single studies, and the horizontal lines through the boxes illustrate the width of the 95% confidence interval. The size of each box represents the weight (%) of each study in the meta-analysis. The hollow diamonds show the pooled estimates, and the width of diamond represent the 95% confidence interval.
menarche, age at menopause and all-cause dementia. We observed no evidence of publication bias with inspection of the funnel plot or with the Egger test (Supplementary eFigure 7).

Discussion

Our findings showed that in categorized meta-analyses, later menopausal age was associated with decreased risk of all-cause dementia, AD, VD and CI. Later menarcheal age was linked to higher risk of VD. Longer reproductive duration was related to lower risk of VD and CI. No clear relationship was observed between age at menarche, reproductive duration and risk of AD. In dose-response analyses, there was a J-shape relationship between menarcheal age and risk of all-cause dementia and AD, and an inverse linear relationship between menopausal age, reproductive duration, postmenopausal estradiol level and risk of all-cause dementia, AD and CI.

In a systematic review published in 2016, Marios et al. found no association of age at menopause, reproductive duration with dementia and CI. However, the review did not use uniform classification for age at menopause, and the reference level differed across studies. Thus, interpretation of the pooled estimates was not easy. Original categories of age at menopause or reproductive duration differed in individual studies. Before generating a pooled estimate, it is necessary to reclassify the original classifications into a standardized one.

By using a standard classification of menopausal age, we found later menopause (≥45 years vs <45 years) was associated with decreased risk of all-cause dementia (0.88, 0.78–0.99), AD, VD. Further, when CI was used as an outcome, later menopause and longer reproductive duration (≥35 years vs <35 years) were linked to lower risk of CI, consistent with the findings from the previous review. Another review found that women with early surgical menopause (≤45 years of age) were associated with a higher risk of all-cause dementia (HR: 1.70, 95%CI: 1.07–2.69) and faster cognitive decline.

Past studies indicated that compared to pre- and perimenopausal women, dramatic decrease in estrogen level after menopause was linked with declined cognitive performance in postmenopausal women. However, other studies with direct measurement of endogenous estradiol (total or bioavailable estradiol (i.e., non-SHBG bound)) or estrone, showed inconclusive relationship between endogenous estrogen and cognitive function or dementia. Some studies reported protective associations between lifelong endogenous estrogen exposure and cognitive function and many failed to identify any association. Research also showed that endogenous oestradiol level after menopause was linked to cognitive decline. One study found that AD was significantly less frequent among women with the highest levels of postmenopausal oestradiol (oestradiol
level range from 5 to 77 pg/mL). Another study found a u-shape relationship between postmenopausal estradiol level and risk of all-cause dementia and AD (estradiol level range from 3.5 to 13 pg/mL). Several reasons may contribute to the inconsistent findings from previous studies. Studies may collect blood samples in different way, e.g., most studies are based on single blood samples, not always draw fasting or in the early morning. Also, the component of estradiol measured may differ in studies. Some measured the total estradiol concentration, while others measured the bioavailable estradiol (i.e., non-SHBG bound). Consistent with previous studies, we did not find a clear dose-response relationship between endogenous estradiol (total or bioavailable estradiol) level and all-cause dementia, however a negative association was observed between estradiol and AD, or estradiol and CI, indicating that a higher estradiol level was related to lower risk of AD and CI. Further, taking menopausal hormone therapy (MHT) may affect the estrogen level after menopause. The effect of MHT on dementia depends on types of MHT and timing of use, and may have net harm to other disease. Thus, guidelines recommend against use of MHT for prevention of chronic disease in asymptomatic menopausal women (grade D recommendations).

Several mechanisms have been proposed to explain why lengths and levels of endogenous estrogen exposure affect the cognitive function decline. First, estrogen can remove oxygen free radicals. Estrogen increases the energy production efficiency of mitochondria, thereby inhibiting the mitochondrial production of free radical oxygen molecules. Thus, loss of estrogens exaggerates aging by decreasing defense against oxidative stress. Second, endogenous estrogens have protective effects on the cardiovascular system. Estrogen increases vasodilatation and inhibits the response of blood vessels to injury and the development of atherosclerosis. Early loss of estrogen, either natural or surgical menopause may increase expression of inflammatory cytokines and increase the risk of cardiovascular diseases. Good vascular health provides adequate blood flow to the brain and benefit central nervous system health. Third, estradiol plays an important role in regulating intracellular Ca²⁺homeostasis and regulating the function of i-type calcium channel, thereby relating to synaptic function and pathological changes of the AD. In addition, elevated estrogen levels can induce the production of new synapses and dendrites in hippocampal CA1 pyramidal cells. Fourth, the epsilon 4 allele of the apolipoprotein gene (APOE-ε4) is thought to elevate MCI and AD risk partly by increasing neuroinflammation. Last, estrogen is also related to morphology of the central nervous system. The voxel-based morphometry (VBM) revealed that early menopause might be underlying causes of nervous system degeneration and depression, because it can lead to gray matter volume reduction in certain brain structures. Also, compared with premenopausal women, there was a significant hippocampal volume reduction bilaterally in postmenopausal women.

Our review has several strengths. Previous reviews only analyzed the association of premenopausal estrogen exposure (used age at menopause or reproductive duration as indicator) and dementia, and no systematic review has been conducted on the relationship between endogenous estrogen after menopause and dementia or CI. We included both pre- and postmenopausal estrogen exposure in present review, providing a life-course perspective into understanding the relationship between endogenous estrogen exposure and dementia. Methodologically, besides using categorized meta-analyses to show results as forest plots, we also used dose-response meta-analyses to show the linear/non-linear relationship between the exposure and outcome across a continuous exposure spectrum.

Our review also has several limitations. First, moderate or high heterogeneity among studies was observed when pooled estimates for age at menopause and dementia, or reproductive duration and dementia was calculated. The women’s age differed in individual studies, raising the possibility of heterogeneity based on age. Nonetheless, I-square values in this review were in the acceptable range, given the use of random-effects models that account for heterogeneity and yield more conservative effect. In addition, although majorities of studies were adjusted for key potential confounders: education, BMI, smoking and postmenopausal HRT status, other confounding factors affecting lifetime estrogen exposure, such as parity, breastfeeding and oral contraceptive use could not be adjusted in most of the studies. Third, dose-response relationship between postmenopausal estradiol level and CI were from cross-sectional studies and may only reflect a cross-sectional association. Fourth, as to postmenopausal estradiol level, although most included studies detected serum estrogen level using fasting blood at 8−11 am, due to the lack of unified detection methods, the estrogen concentration might fluctuate across studies. Last, limited by the number of studies included, publication bias (using funnel plots) were only assessed for the associations of menopausal age, menarchal age and all-cause dementia.

Later menopause was consistently linked to lower risk of dementia and CI, while menarchal age showed a J-shape relationship with dementia. There was an inverse relationship between higher concentration of postmenopausal estrogen level and risk of AD and CI. Our findings may support the hypothesis that endogenous estrogen loss at menopause confers increased vulnerability to AD in women. Our findings also indicated estrogen exposure indicators before or after menopause might have different effect on VD, with former protective and latter non or harmful. Longitudinal, repeat
measure designs are needed to examine the association between life-time estrogen exposure and risk of subtypes of dementia using direct measure of serum level of endogenous estrogen before and after menopause.

Funding
Start-up Foundation for Scientific Research in Shandong University.

Contributors
CF and WH searched databases, extracted data, did statistical analyses, and drafted the manuscript. NS, SSV, SRM, and DZ contributed to critical revision of the manuscript. DZ was the study supervisor and conceived the study design and contributed to interpretation of the results.

Declaration of interest
Dr. Virani reports grants from Department of Veterans Affairs, NIH, World Heart Federation, Tahir and Jooma Family, other from being an associate editor for Innovations of American College of Cardiology (acc.org), outside the submitted work. All the other authors report no conflicts.

Data sharing statement
The study protocol and statistical analysis plan are available upon request to the corresponding author.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.eclinm.2021.101236.

References
1. Sindi S, Kereholt I, Ngandu T, et al. Sex differences in dementia and response to a lifestyle intervention: evidence from Nordic population-based studies and a prevention trial. Alzheimer's Dementia 2021;17(5):1156–78.
2. Cao Q, Tan CC, Xu W, et al. The Prevalence of Dementia: a Systematic Review and Meta-Analysis. J Alzheimers Dis 2020;69(1):1157–66.
3. Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health 2020;5(2):e661–71.
4. Mielle MM. Sex and gender differences in Alzheimer's disease dementia. Psychiatr Times 2016;33(11):14–7.
5. Nebel RA, Aggarwal NT, Barnes LL, et al. Understanding the impact of sex and gender in Alzheimer's disease: a call to action. Alzheimer's Dementia 2018;14(1):171–83.
6. Yoo JE, Shin DW, Han K, et al. Female reproductive factors and the risk of dementia: a nationwide cohort study. Eur J Neurol 2020;27(8):1448–58.
7. Shimizu Y, Sawada N, Iwasaki M, et al. Reproductive history and risk of cognitive impairment in Japanese women. Maturitas 2019;128:22–8.
8. Li FD, Lin JF, Ying XH, et al. A U-shaped Association of Breastfeeding Duration with Cognitive Impairment in Chinese Postmenopausal Women. Sci Rep 2020;10(1):6984.
9. Chou HT, Wu PY, Huang JC, Chen SC, Ho WY. Late menarche, not reproductive period, is associated with poor cognitive function in postmenopausal women in Taiwan. Int J Environ Res Public Health 2021;18(9).
10. Gilsanz P, Lee C, Corrada MM, Kawas CH, Quesenberry Jr. CP, Whitmer RA. Reproductive period and risk of dementia in a diverse cohort of health care members. Neurology 2019;92(7):e2205–14.
11. Prince MJ, Acosta D, Guerra M, et al. Reproductive period, endogenous estrogen exposure and dementia incidence among women in Latin America and China: A 10/56 population-based cohort study. PLoS ONE 2018;13(2):e0192889.
12. Najar J, Ostling S, Warren M, et al. Reproductive period and dementia: a 44-year longitudinal population study of Swedish women. Alzheimers Dement 2020;69(8):1153–67.
13. Geerlings MI, Ruitenberg A, Witteman JC, et al. Reproductive period and risk of dementia in postmenopausal women. JAMA 2002;288(11):1275–81.
14. Georgakis MK, Kalogrouli El, Diamantaras AA, et al. Age at menopause and duration of reproductive period in association with dementia and cognitive function: a systematic review and meta-analysis. Psychoneuroendocrinology 2016;73:224–31.
15. Mancuso H, Eldery NY, Segal R, Harttzena A. Duration of reproductive years and the risk of cardiovascular and cerebrovascular events in older women: insights from the national health and nutrition examination survey. J Womens Health (Larchmt) 2017;26(10):2047–52.
16. Ragon NL, Magnusson C, Johansson AL, Pedersen NL, Ehrman S, Gatz M. Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: a preliminary study. Psychoneuroendocrinology 2009;34(6):538–67.
17. Li FD, He F, Chen TR, et al. Reproductive history and risk of cognitive impairment in elderly women: a cross-sectional study in eastern China. J Alzheimers Dis 2016;59(1):239–47.
18. Lehrum CE, van der Schoor YT, de Jong FH, Pols HA, Grobbee DE, Lamberts SW. Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf) 2005;63(3):39–50.
19. Yaffe K, Barnes D, Lindquist K, et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging 2007;28(4):371–8.
20. Koyama AK, Tweorger SS, Elissen AH, et al. Endogenous sex hormones and cognitive function in older women. Alzheimers Dement 2016;12(7):757–65.
21. CarcaiIlin I, BralII-Tabard S, Ancelin ML, et al. High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology 2014;83(6):594–11.
22. Ravaglia G, Forti P, Maioli F, et al. Endogenous sex hormones as risk factors for dementia in elderly men and women. J Gerontol A Biol Sci Med Sci 2007;62(10):1035–41.
23. Lacross AE, Gondal H, Langaker MD, Physiology, Menarche. StatPearls. Treasure Island (FL): StatPearls Publishing; 2021 Copyright ©StatPearls Publishing LLC.; 2021.
24. Takahashi TA, Menopause Johnson KM. Med Clin North Am 2015;99(6):321–34.
25. Low LF, Anstey KJ, Corrada MM, Kawas CH, Quesenberry Jr. CP, Christensen H. Reproductive history and duration of reproductive period in association with dementia and cognitive function in older women. Med Clin North Am 2015;99(6):321–34.
26. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014. 2014.
27. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(5):503–5.
28. Roestam A, Dubé C, Cranney A, et al. Celiac disease. Evid Rep Technol Assess (Summ) 2004(104):1–6.
29. Hu J, Dong Y, Chen X, et al. Prevalence of suicide attempts among Chinese adolescents: a meta-analysis of cross-sectional studies. Compr Psychiatry 2015;64:78–89.
30. Fieth KM, Jette N, Roberts JI, et al. The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci 2016;43(5):53–50.
31. Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 2013;381(9882):2016–23.
32 Rajan KB, Weaver J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement 2019;15(1):7–17.
33 Overton M, Pihlsgard M, Elmstahl S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex. Dement Geriatr Cogn Disord 2019;47(1–2):210–12.
34 Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:31–50.
35 Huggins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2001;322(7261):375–80.
36 Yoo JE, Shin DW, Han K, et al. Female reproductive factors and the risk of dementia: a nationwide cohort study. Eur J Neurol 2020;27(3):144–58.
37 Coppus AM, Evenhuis HM, Verberne GJ, et al. Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome. J Alzheimers Dis 2020;73(2):543–50.
38 Geerlings MI, Launer LJ, de Jong FH, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 2003;53(5):507–15.
39 Gilhaz P, Corrada MM, Kwas HC, Quesenberry CP, Lee C, Whitmer RA. Prevalence of endogenous estrogens and risk of dementia in women: the Guangzhou Biobank Cohort Study. Psychoneuroendocrinology 2021;116(6):864–73.
40 Hong X, Zhang X, Li H. A case-control study of endogenous estrogen and risk of Alzheimer’s disease. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(3):379–82.
41 Hu J, Chu K, Song Y, et al. Higher level of circulating estradiol is associated with lower frequency of cognitive impairment in South-east China. Gynecol Endocrinol 2017;33(1):340–4.
42 Manly JJ, Merchant CA, Jacobs DM, et al. Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women. Neurology 2000;54(4):383–7.
43 Pagano-Hill A, Corrada MM, Kawasaki CH. Prior endogenous and exogenous estrogen and incident dementia in the 10th decade of life: the 90+ Study. Climacteric 2020;23(5):311–5.
44 Pagano-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Ann J Epidemiol 1993;140(3):236–61.
45 Ryan J, Seidl J, Carriere I, et al. Impact of a premature menopause on cognitive function in later life. JBG 2014;421(11):1729–39.
46 Schupf N, Pang D, Patel BN, et al. Onset of dementia is associated with age at menopause in women with Down syndrome. Alzheimer Dis Assoc Disord 2003;17(4):379–82.
47 Schupf N, Carriere I, Scali J, Ritchie K, Ancelin ML. Life-time estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinology 2009;34(2):287–98.
48 Grady D. Evidence for Postmenopausal Hormone Therapy to Prevent Chronic Conditions: success, failure, and Lessons Learned. JAMA Intern Med 2016;176(2):185–6.
49 Stirona C, Duckles SP, Krause DN, Proccacio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 2005;68(1):959–65.
50 Chakrabarti M, Das A, Samantary S, et al. Molecular mechanisms of estrogen for neuroprotection in spinal cord injury and traumatic brain injury. Rev Neurosci 2016;27(9):271–87.
51 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(21):1801–11.
52 Mazzucca MQ, Mata KM, Li W, Rangan SS, Khalil RA. Estrogen Receptor Subtypes Mediate Distinct Microvascular Dilatation and Reduction in [Ca2+]in in Mesenteric Microvessels of Female Rat. Journal of Pharmacology & Experimental Therapeutics 2015;352(2):291–304.
53 Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019;4(11):e553–604.
54 Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020;35(8):1931–43.
55 Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther 2012;135(3):54–79.
56 Thor D, Uchizono JA, Lin-Cereghino GP, Rahimian R. The effect of 17 beta-estradiol on intracellular calcium homoeostasis in human endothelial cells. Eur J Pharmacol 2006;526(1–3):193–9.
57 Brake WG, Alves SE, Dunlop JC, et al. Novel target sites for estrogen action in the dorsal hippocampus: an examination of synaptic proteins. Endocrinology 2001;142(5):1782–93.
58 Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med 2007;4(11):e2002545.
59 VanDusen K, Elewarsisu S, Moretti EW, et al. The MARBLE Study Protocol: modulating ApoE Signaling to Reduce Brain Inflammation, Delirium, and Postoperative Cognitive Dysfunction. J Alzheimers Dis 2020;75(4):1319–28.
60 Lu W, Guo W, Hou K, et al. Grey matter differences associated with age and sex hormone levels between premenopausal and perimenopausal women: a voxel-based morphometry study. J Neuroendocrinol 2018;30(2):e12655.
61 Goto M, Abe O, Miyati T, et al. Tesla MRI detects accelerated hippocampal volume reduction in postmenopausal women. J Magn Reson Imaging 2011;33(4):48–53.